Cancer Biology & Medicine May 15 2026 Although cancer immunotherapy has transformed treatment by harnessing the immune system to eliminate tumors, only a small subset of patients benefit. Many solid tumors remain "cold," characterized by poor immune cell infiltration and resistance to immune checkpoint blockade (ICB). In addition, traditional immunotherapies such as cytokines and checkpoint inhibitors often cause severe immune-related adverse events due to off-target toxicity, poor tumor